Our research focused on the development of therapeutic antibody and related bio-pharmaceutical including chimeric antigen T cell receptor (CAR) T cell therapy and antibody drug conjugate. One of our antibody has finished Phase I clinical trial and entering Phase Ib/II phase (ClinicalTrials.gov Identifier: NCT02499224). We collaborate with research groups in other institute including Institute Pasteur Korea (IPK) and many biotechnology companies for the successful development of the drug candidates.
We also perform B cell immune repertoire profiling with Next Generation Sequencing (NGS) to understand the interaction of immune system and various antigens. This research provides us the clues for the development of autoimmune disease based on humoral immunity and immunological response to oncogenesis.
Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine
Department of Biomedical Sciences, Seoul National University College of Medicine
Laboratory of Antibody Engineering, Cancer Research Institute, Seoul National University
Suites 506-515, Samsung Cancer Research Building
Daehakro 103, Seoul 03080, South Korea (Rep. of Korea)
Last Update: 15 August 2018